Summary by Moomoo AI
On May 20, 2024, Avalo Therapeutics, Inc. received a notice from the Nasdaq Listing Qualifications Department indicating that the company does not meet the Nasdaq Capital Market's continued listing requirement of maintaining a minimum of $2,500,000 in stockholders' equity. The notice was issued following Avalo Therapeutics' report of negative $112.6 million in stockholders' equity for the quarter ended March 31, 2024. The company has been given 45 days, until July 5, 2024, to submit a plan to regain compliance. If the plan is accepted, Nasdaq may grant up to 180 days for the company to demonstrate compliance. Avalo Therapeutics' common stock will continue to trade on the Nasdaq under the symbol 'AVTX' during this period. The company is exploring options to regain compliance, but there is no guarantee that...Show More